Using more tumor-specific PET-tracers, such as the prostate specific membrane antigen (PSMA) in prostate cancer [31], or more recently fibroblast activation protein inhibitor (FAPI)-targeting agents [32], could significantly increase both the specificity and sensitivity of the technique. The gene discussed is FOLH1; the disease is prostate carcinoma.